8-K: Collegium Pharmaceutical Announces Board Changes and New Executive Appointment

Collegium Pharmaceutical reports director resignations, the nomination of a new director, and the appointment of a new Executive Vice President and General Counsel.

Summary

• Collegium Pharmaceutical announced that Michael Heffernan and Gwen Melincoff will not stand for re-election at the 2025 Annual Meeting of Shareholders.
• Michael Heffernan, the founder and current Chairman of the Board, will retire from the Board at the Annual Meeting after serving since October 2003.
• Gwen Melincoff, a director since 2017, will also retire from the Board at the Annual Meeting.
• Gino Santini, the Company's lead independent director since 2018, has been named Chairman of the Board, effective immediately following the Annual Meeting.
• Dr. Carlos Paya has been nominated to stand for election to the Board at the 2025 Annual Meeting of Shareholders.
• Dr. Paya has extensive experience in the pharmaceutical and biotechnology industries, including roles at Abingworth LLP, Vaxcyte, Highlight Therapeutics, Ysios Capital, Launch Therapeutics, Standard BioTools, Mallinckrodt Pharmaceuticals, Immune Design Corp, Elan Corporation, and Eli Lilly & Company.
• The Company announced the appointment of David Dieter as Executive Vice President and General Counsel, effective March 17, 2025.
• Mr. Dieter previously served as an independent legal advisor and held positions at Horizon Therapeutics, Takeda, Freeborn & Peters, and Perkins Coie.

Sentiment

Score: 7

Explanation: The announcement is generally neutral, reflecting standard corporate governance activities. The addition of experienced personnel is a positive, but the departure of long-standing board members is a mixed signal.

Positives

• The appointment of David Dieter as Executive Vice President and General Counsel brings significant legal and industry experience to Collegium Pharmaceutical.
• The nomination of Dr. Carlos Paya to the Board adds extensive pharmaceutical and biotechnology expertise.

Future Outlook

The company is focused on board refreshment and succession planning.

Management Comments

• The Company extends its deepest gratitude to each of Mr. Heffernan and Ms. Melincoff for their distinguished service to the Board and lasting contributions to the Company.
• Mr. Heffernan's and Ms. Melincoff's decisions not to stand for re-election are a part of the Board's continued focus of board refreshment and board succession planning, and not the result of any disagreement with the Company.

Industry Context

Board refreshment and executive appointments are common in the pharmaceutical industry to bring in new perspectives and expertise.

Comparison to Industry Standards

• The board changes and executive appointments are typical activities for publicly traded pharmaceutical companies.
• Companies like Amgen, Merck, Eli Lilly, and Takeda are often benchmarks for executive talent and corporate governance practices in the pharmaceutical industry.

Management Changes

Stakeholder Impact

• Shareholders may react to the board changes and new executive appointment.
• Employees may be affected by the changes in leadership.

Next Steps

• Election of Dr. Carlos Paya at the 2025 Annual Meeting of Shareholders.
• Gino Santini to assume the role of Chairman of the Board following the Annual Meeting.

Key Dates